{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:26:22Z","timestamp":1770960382324,"version":"3.50.1"},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.13900","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T17:39:04Z","timestamp":1686073144000},"source":"Crossref","is-referenced-by-count":5,"title":["Efficacy, toxicity and prognostic factors of pyrotinib\u2011involved neoadjuvant therapy in HER2\u2011positive breast cancer: A retrospective study"],"prefix":"10.3892","volume":"26","author":[{"given":"Hao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong 511400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailing","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong 511400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong 511400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"key20230622100520_b1-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.JAA.0000580524.95733.3d","article-title":"Overview of breast cancer","volume":"32","author":"Watkins","year":"2019","journal-title":"JAAPA"},{"key":"key20230622100520_b2-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"key20230622100520_b3-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/GCO.0000000000000677","article-title":"Frontiers in HER2-positive breast cancer in 2020","volume":"33","author":"Peddi","year":"2021","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key20230622100520_b4-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positive breast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"key20230622100520_b5-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco-20-123","article-title":"Neoadjuvant treatment for HER2-positive breast cancer","volume":"9","author":"Takada","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"key20230622100520_b6-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"102033","DOI":"10.1016\/j.ctrv.2020.102033","article-title":"HER2-positive advanced breast cancer treatment in 2020","volume":"88","author":"Cesca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20230622100520_b7-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20230622100520_b8-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20230622100520_b9-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"909426","DOI":"10.3389\/fonc.2022.909426","article-title":"Pegylated liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant treatment for HER2-positive breast cancer patients: A phase II and biomarker study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"key20230622100520_b10-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3390\/cancers14112596","article-title":"BERENICE final analysis: Cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer","volume":"14","author":"Dang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20230622100520_b11-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-018-1013-4","article-title":"Pyrotinib: First global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"key20230622100520_b12-ol-26-1-13900","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","journal-title":"Am J Cancer Res"},{"key":"key20230622100520_b13-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1002\/cam4.4335","article-title":"Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"key":"key20230622100520_b14-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20230622100520_b15-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.21037\/gs-21-770","article-title":"Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: A retrospective case-series study","volume":"10","author":"Yao","year":"2021","journal-title":"Gland Surg"},{"key":"key20230622100520_b16-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"e1909","DOI":"10.1002\/onco.13546","article-title":"Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I\u2013III HER2-positive breast cancer: A phase II clinical trial","volume":"25","author":"Xuhong","year":"2020","journal-title":"oncologist"},{"key":"key20230622100520_b17-ol-26-1-13900","article-title":"Efficacy and safety of neoadjuvant pyrotinib plus docetaxel\/liposomal doxorubicin\/cyclophosphamide for HER2-positive breast cancer","author":"Tian","year":"2022","journal-title":"Ir J Med Sci"},{"key":"key20230622100520_b18-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejca.2022.01.022","article-title":"Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): A multicentre phase 2 trial","volume":"165","author":"Liu","year":"2022","journal-title":"Eur J Cancer"},{"key":"key20230622100520_b19-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-018-2301-9","article-title":"The new TNM-based staging of breast cancer","volume":"472","author":"Cserni","year":"2018","journal-title":"Virchows Arch"},{"key":"key20230622100520_b20-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST-learning from the past to build the future","volume":"14","author":"Liti\u00e8re","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20230622100520_b21-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20230622100520_b22-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"216","DOI":"10.21037\/gs-21-911","article-title":"Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: An exploratory phase II trial","volume":"11","author":"Zhong","year":"2022","journal-title":"Gland Surg"},{"key":"key20230622100520_b23-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"699323","DOI":"10.3389\/fonc.2021.699323","article-title":"Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: A multicenter, prospective, real-world study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"key20230622100520_b24-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"616443","DOI":"10.3389\/fonc.2021.616443","article-title":"The synergistic effects of pyrotinib combined with adriamycin on HER2-positive breast cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"key20230622100520_b25-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clcc.2022.07.003","article-title":"Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: A result from HER2-FUSCC-G study","volume":"21","author":"Chang","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"key20230622100520_b26-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"329","DOI":"10.25122\/jml-2019-0115","article-title":"The dual blockade in the neoadjuvant setting of HER-2 positive early-stage breast cancer","volume":"12","author":"Pop","year":"2019","journal-title":"J Med Life"},{"key":"key20230622100520_b27-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"key20230622100520_b28-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"855512","DOI":"10.3389\/fonc.2022.855512","article-title":"Pyrotinib-containing neoadjuvant therapy in patients with HER2-positive breast cancer: A multicenter retrospective analysis","volume":"12","author":"Mao","year":"2022","journal-title":"Front Oncol"},{"key":"key20230622100520_b29-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.21037\/gs-21-794","article-title":"Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: A cohort study","volume":"10","author":"Li","year":"2021","journal-title":"Gland Surg"},{"key":"key20230622100520_b30-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/SPC.0b013e32835ec861","article-title":"Mechanisms of TKI-induced diarrhea in cancer patients","volume":"7","author":"Bowen","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"key20230622100520_b31-ol-26-1-13900","doi-asserted-by":"publisher","first-page":"e126444","DOI":"10.1172\/jci.insight.126444","article-title":"Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea","volume":"4","author":"Duan","year":"2019","journal-title":"JCI Insight"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T19:40:21Z","timestamp":1687462821000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.13900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,6]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.13900","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"314"}}